文献速递细菌感染、耐药与抗菌药物

美国女性门诊尿路大肠埃希菌耐药趋势:2011-2019年产ESBL菌株上升

Antimicrobial Resistance Trends in Urine Escherichia coli Isolates From Adult and Adolescent Females in the United States From 2011 to 2019: Rising ESBL Strains and Impact on Patient Management.
PubMed 文献 · Clin Infect Dis · 2021-01-01

该回顾性研究分析了2011-2019年美国≥12岁女性门诊尿培养大肠埃希菌分离株的耐药趋势,共纳入1 513 882株。结果显示,对甲氧苄啶-磺胺甲噁唑、氟喹诺酮类和呋喃妥因不敏感的总体患病率分别为25.4%、21.1%和3.8%,ESBL+占6.4%,≥2种耐药表型占14.4%,≥3种占3.8%。模型显示ESBL+菌株年均相对增加7.7%(95%CI 7.2-8.2%),≥3种耐药表型年均增加2.7%(95%CI 2.2-3.2%),且不同人口普查区域间耐药患病率存在显著差异(P<.001)。

要点

  • 美国女性门诊尿源大肠埃希菌对常用口服抗生素耐药率较高,经验性治疗需参考当地耐药数据。
  • ESBL+菌株年均相对增加7.7%,≥3种耐药表型年均增加2.7%,多重耐药呈上升趋势。
  • 耐药患病率在美国不同人口普查区域间存在显著差异,应结合区域耐药率指导经验用药。

核心结论

  • 美国门诊女性尿源大肠埃希菌耐药患病率高,多重耐药表型在研究期间增加,且区域差异显著。
  • 了解区域耐药率有助于指导社区获得性uUTI的经验性治疗并提示医生关注耐药负担。

研究设计与样本

  • 回顾性研究,使用Becton, Dickinson and Company Insights Research Database 2011-2019年数据。
  • 采用广义估计方程模型分析耐药随时间及美国人口普查区域的变化趋势。

主要发现

  • 对甲氧苄啶-磺胺甲噁唑、氟喹诺酮类和呋喃妥因不敏感的总体患病率分别为25.4%、21.1%和3.8%。
  • 6.4%的分离株为ESBL+,14.4%具有≥2种耐药表型,3.8%具有≥3种耐药表型。
  • 模型显示ESBL+菌株年均相对增加7.7%(95%CI 7.2-8.2%),≥3种耐药表型年均增加2.7%(95%CI 2.2-3.2%),均P<.0001。
  • 模型显示美国不同人口普查区域间耐药患病率存在显著差异(P<.001)。

临床怎么用

  • 社区起始uUTI经验性治疗应参考区域耐药率,尤其关注ESBL+和多重耐药菌株的上升趋势。
  • 对常用口服药物耐药率较高,临床医生应了解当地耐药数据以优化经验性用药选择。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Uncomplicated urinary tract infection (uUTI) is predominantly caused by Escherichia coli, which has increasing antimicrobial resistance (AMR) at the United States (US)-community level. As uUTI is often treated empirically, assessing AMR is challenging, and there are limited contemporary data characterizing period prevalence in the US. METHODS: This was a retrospective study of AMR using Becton, Dickinson and Company Insights Research Database (Franklin Lakes, New Jersey, US) data collected 2011-2019. Thirty-day, nonduplicate Escherichia coli urine isolates from US female outpatients (aged ≥12 years) were included. Isolates were evaluated for nonsusceptibility (intermediate/resistant) to trimethoprim-sulfamethoxazole, fluoroquinolones, or nitrofurantoin, and assessed for extended-spectrum β-lactamase production (ESBL+) and for ≥2 or ≥3 drug-resistance phenotypes. Generalized estimating equations were used to model AMR trends over time and by US census region. RESULTS: Among 1 513 882 E. coli isolates, the overall prevalence of isolates nonsusceptible to trimethoprim-sulfamethoxazole, fluoroquinolones, and nitrofurantoin was 25.4%, 21.1%, and 3.8%, respectively. Among the isolates, 6.4% were ESBL+, 14.4% had ≥2 drug-resistance phenotypes, and 3.8% had ≥3. Modeling demonstrated a relative average yearly increase of 7.7% (95% confidence interval [CI], 7.2-8.2%) for ESBL+ isolates and 2.7% (95% CI, 2.2-3.2%) for ≥3 drug-phenotypes (both P < .0001). Modeling also demonstrated significant variation in AMR prevalence between US census regions (P < .001). CONCLUSIONS: Period prevalence of AMR among US outpatient urine-isolated E. coli was high, and for multidrug-resistance phenotypes increased during the study period with significant variation between census regions. Knowledge of regional AMR rates helps inform empiric treatment of community-onset uUTI and highlights the AMR burden to physicians.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Kaye KS, Gupta V, Mulgirigama A, et al. Antimicrobial Resistance Trends in Urine Escherichia coli Isolates From Adult and Adolescent Females in the United States From 2011 to 2019: Rising ESBL Strains and Impact on Patient Management. Clin Infect Dis. 2021. PMID: 34143881. doi:10.1093/cid/ciab560

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。